Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ablynx N.V.
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
A syndicate of high-profile investors are backing the Barcelona-based firm's bid to develop biologics targeting metastatic-initiating cells and lipid metabolism.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Ablynx NV